$CRISJul 6, 2026, 9:30 AM ETAI processed
CRIS: First six patients consented in TakeAim CLL; initial data due Dec 2026
AI Summary
Curis (CRIS) said it has consented the first six patients in its TakeAim CLL Phase 2 study of emavusertib plus zanubrutinib, expects to dose five CLL patients by end-July 2026 and plans to report initial CLL data in December 2026. The open-label trial enrolls MRD+ CLL patients already on zanubrutinib to test whether adding emavusertib (IRAK4/TLR pathway inhibitor) to a BTK inhibitor produces deeper responses (e.g., CR or undetectable MRD) versus BTKi alone.
Positives
- Consented first six patients in TakeAim CLL Phase 2 (enrollment milestone reached)
- Guidance to dose five CLL patients by end-July 2026 and initial data expected December 2026
- Study targets MRD+ CLL patients on zanubrutinib to test dual NF-kB blockade (TLR + BCR) aimed at deeper responses
Negatives
- Enrollment is still early (only six patients consented), so data will be preliminary and limited
- Company discloses it does not have sufficient cash to support operations for the next 12 months absent additional funding
- Clinical and regulatory risks remain (forward-looking timelines and outcomes not guaranteed)